Recalls & Warnings April 20, 2026 FDA Warns Consumers Not to Use Certain Pain Relief Supplements On April 7, 2026, the FDA warned consumers not to purchase or use eight supplements labeled as containing hyaluronic acid and promoted for pain relief because they contain undeclared drugs
A placebo-controlled study
For healthcare systems, it introduces the possibility of new treatment pathways that may, over time, reshape both patient outcomes and cost structures
The evidence below is per-compound, plus the CagriSema (cagrilintide + semaglutide) Phase 3 data as the closest analog
Endocrine 75(3):718724 Wilding JPH et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
Q 4: What if Im not losing weight after 3 months